Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer

NCT01546987 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT01546987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01546987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2012
Completion date
September 4, 2025
Enrollment
239 (actual)
Sites
172

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer